A methadone-based specialty made available 4 years ago, Zoryon has no longer been marketed since the end of November, due to lack of success.
Zoryon, methadone hydrochloride which comes in multiple dosages (5 mg, 10 mg, 20 mg and 40 mg) in the form of capsules and syrups, was only distinguished from Methadone AP-HP by its indication: in basic treatment cancer pain of moderate to severe intensity in patients aged 15 and over who are not adequately relieved by other opioids, due to poor effectiveness insufficient and/or excessive adverse effects. Methadone AP-HP is indicated in the replacement treatment of major drug dependence on opioids.
“The objective of marketing Zoryon was to be able to separate methadone hydrochloride prescriptions based on these two distinct indications. This objective could not be achieved after four years of marketing,” reports the National Agency for the Safety of Medicines and Health Products (ANSM). Hospital establishments, which already listed Methadone AP-HP, did not add Zoryon to their listing.
Bouchara-Recordati Laboratories and AP-HP (Assistance publique – Hôpitaux de Paris) have therefore decided to stop marketing Zoryon, effective since November 28, 2024, but stocks can be sold until they are exhausted or expiration, and can run until the end of 2025.
“This marketing stoppage is not linked to a problem with the quality, safety, or effectiveness of the drug,” would like to clarify the ANSM.
Health
